{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:02:44Z","timestamp":1784685764248,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation,","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04429-5","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:55:04Z","timestamp":1779191704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early increase of CD103 expression on peripheral PD-1+\u2009CD8+\u2009T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Satoko","family":"Sumimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"4429_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ags3.12835","volume":"8","author":"T Higashi","year":"2024","unstructured":"Higashi T, Kurokawa Y (2024) Incidence, mortality, survival, and treatment statistics of cancers in digestive organs\u2014Japanese cancer statistics 2024. Ann Gastroenterol Surg 8:1\u20138","journal-title":"Ann Gastroenterol Surg"},{"key":"4429_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"4429_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-022-00950-5","volume":"20","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Toh Y, Ishihara R et al (2023) Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1\u201328","journal-title":"Esophagus"},{"key":"4429_CR4","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Lagergren J, Fitzgerald RC et al (2017) Oesophageal cancer. Nat Rev Dis Primers 3:17048","journal-title":"Nat Rev Dis Primers"},{"key":"4429_CR5","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41416-022-01726-5","volume":"126","author":"T Makino","year":"2022","unstructured":"Makino T, Yamasaki M, Tanaka K et al (2022) Multicenter randomized trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. Br J Cancer 126:1555\u20131562","journal-title":"Br J Cancer"},{"key":"4429_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41416-023-02151-y","volume":"128","author":"Y Nose","year":"2023","unstructured":"Nose Y, Makino T, Tatsumi M et al (2023) Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes. Br J Cancer 128:1879\u20131887","journal-title":"Br J Cancer"},{"key":"4429_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/SLA.0000000000002808","volume":"270","author":"T Makino","year":"2019","unstructured":"Makino T, Yamasaki M, Tanaka K et al (2019) Metabolic tumor volume change predicts long-term survival and histological response to preoperative chemotherapy in locally advanced esophageal cancer. Ann Surg 270:1090\u20131095","journal-title":"Ann Surg"},{"key":"4429_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/SLA.0000000000003129","volume":"271","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Makino T, Yamasaki M et al (2020) The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance. Ann Surg 271:875\u2013884","journal-title":"Ann Surg"},{"key":"4429_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/sj.bjc.6605313","volume":"101","author":"T Makino","year":"2009","unstructured":"Makino T, Yamasaki M, Takeno A et al (2009) Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer 101:1298\u20131306","journal-title":"Br J Cancer"},{"key":"4429_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","volume":"104","author":"M Yamasaki","year":"2011","unstructured":"Yamasaki M, Makino T, Masuzawa T et al (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707\u2013713","journal-title":"Br J Cancer"},{"issue":"3","key":"4429_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10388-025-01120-z","volume":"22","author":"S Nakai","year":"2025","unstructured":"Nakai S, Makino T, Momose K et al (2025) Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable\/recurrent esophageal squamous cell carcinoma. Esophagus 22(3):360\u2013372","journal-title":"Esophagus"},{"issue":"3","key":"4429_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10388-024-01056-w","volume":"21","author":"T Makino","year":"2024","unstructured":"Makino T, Nakai S, Momose K et al (2024) Efficacy and survival of nivolumab treatment for recurrent\/unresectable esophageal squamous cell carcinoma: real-world clinical data from a large multiinstitutional cohort. Esophagus 21(3):319\u2013327","journal-title":"Esophagus"},{"key":"4429_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506\u20131517","journal-title":"Lancet Oncol"},{"key":"4429_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"T Kojima","year":"2021","unstructured":"Kojima T, Shah MA, Muro K et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191\u20131203","journal-title":"N Engl J Med"},{"key":"4429_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386:449\u2013462","journal-title":"N Engl J Med"},{"key":"4429_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771","journal-title":"Lancet"},{"key":"4429_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA et al (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"4429_CR18","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer. JAMA Oncol 4:e180013","journal-title":"JAMA Oncol"},{"key":"4429_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202\u2013206","journal-title":"Nat Genet"},{"key":"4429_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA et al (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2:46\u201354","journal-title":"JAMA Oncol"},{"issue":"7","key":"4429_CR21","doi-asserted-by":"publisher","first-page":"119781","DOI":"10.1016\/j.bbamcr.2024.119781","volume":"1871","author":"Y Liang","year":"2024","unstructured":"Liang Y, He S, Liu Q et al (2024) Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma. Biochim Biophys Acta Mol Cell Res 1871(7):119781","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"6","key":"4429_CR22","doi-asserted-by":"publisher","first-page":"111167","DOI":"10.1016\/j.humimm.2024.111167","volume":"85","author":"S He","year":"2024","unstructured":"He S, Liu Q, Luo S et al (2024) Immune cell infiltration and drug sensitivity in PIK3CA-mutated esophageal squamous cell carcinoma: A TCGA database analysis. Hum Immunol 85(6):111167","journal-title":"Hum Immunol"},{"key":"4429_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","volume":"1","author":"S Valpione","year":"2020","unstructured":"Valpione S, Galvani E, Tweedy J et al (2020) Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 1:210\u2013221","journal-title":"Nat Cancer"},{"key":"4429_CR24","doi-asserted-by":"crossref","unstructured":"Matsumoto Y, Toyozumi T, Shimada H. Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review. Ann Gastroenterol Surg. 2025;15;10(1):54\u201366.","DOI":"10.1002\/ags3.70095"},{"key":"4429_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ et al (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60\u201365","journal-title":"Nature"},{"key":"4429_CR26","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S et al (2017) Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1\u2013targeted therapy. Proc Natl Acad Sci U S A 114:4993\u20134998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4429_CR27","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1158\/1538-7445.AM2015-3475","volume":"75","author":"F Djenidi","year":"2015","unstructured":"Djenidi F, Adam J, Goubar A et al (2015) CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells associated with improved survival in lung cancer. Cancer Res 75:3475\u20133486","journal-title":"Cancer Res"},{"key":"4429_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb JR, Milne K, Watson P et al (2014) Tumor-infiltrating lymphocytes expressing the tissue-resident memory marker CD103 are associated with improved survival in ovarian cancer. Clin Cancer Res 20:434\u2013444","journal-title":"Clin Cancer Res"},{"key":"4429_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","volume":"273","author":"S Urakawa","year":"2021","unstructured":"Urakawa S, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T et al (2021) Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg 273:1141\u20131149","journal-title":"Ann Surg"},{"issue":"1","key":"4429_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00262-022-03240-2","volume":"72","author":"Y Nose","year":"2023","unstructured":"Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K et al (2023) The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer. Cancer Immunol Immunother 72(1):169\u2013181","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"4429_CR31","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.1245\/s10434-021-10025-x","volume":"28","author":"T Ishida","year":"2021","unstructured":"Ishida T, Makino T, Yamasaki M, Yamashita K, Tanaka K, Saito T et al (2021) Quantity and quality of skeletal muscle as an important predictor of clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy. Ann Surg Oncol 28(12):7185\u20137195","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4429_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.surg.2019.07.033","volume":"166","author":"T Ishida","year":"2019","unstructured":"Ishida T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T et al (2019) Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy. Surgery 166(6):1041\u20131047","journal-title":"Surgery"},{"key":"4429_CR33","first-page":"1856","volume":"189","author":"K Franciszkiewicz","year":"2013","unstructured":"Franciszkiewicz K, Le Floc\u2019h A, Boutet M et al (2013) CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes polarization of lytic granules and enhances tumor cell killing. J Immunol 189:1856\u20131865","journal-title":"J Immunol"},{"key":"4429_CR34","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"4429_CR35","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152","journal-title":"Lancet Oncol"},{"key":"4429_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7:306","journal-title":"J Immunother Cancer"},{"key":"4429_CR37","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"Y Hayashi","year":"2023","unstructured":"Hayashi Y, Makino T, Sato E et al (2023) Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer 128:2175\u20132185","journal-title":"Br J Cancer"},{"key":"4429_CR38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/SLA.0000000000005104","volume":"277","author":"T Noma","year":"2023","unstructured":"Noma T, Makino T, Ohshima K et al (2023) Immunoscore signatures in surgical specimens and tumor-infiltrating lymphocytes in pretreatment biopsy predict treatment efficacy and survival in esophageal cancer. Ann Surg 277:528\u2013537","journal-title":"Ann Surg"},{"key":"4429_CR39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Nature 545:446\u2013451","journal-title":"Nature"},{"key":"4429_CR40","first-page":"185","volume":"26","author":"SV Bratman","year":"2020","unstructured":"Bratman SV, Yang SYC, Iafolla MAJ et al (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor immunotherapy. Nat Med 26:185\u2013192","journal-title":"Nat Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04429-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:36:17Z","timestamp":1784684177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04429-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4429"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04429-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest T.M. received lecture fees from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb. Y.K. received lecture fees and grant from Ono Pharmaceutical Co., Ltd and lecture fees from Bristol-Myers Squibb. Y.D. received lecture fees and grant from Ono Pharmaceutical Co., Ltd and lecture fees from Bristol-Myers Squibb.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"185"}}